Nextrials, Inc., a leader in clinical research software and services, today announced that ArQule, Inc., a developer of novel small molecule therapies to treat cancer, has selected its award-winning clinical trial data collection and management product, Prism(R), for use in an ongoing Phase I/II clinical trial. ArQule will deploy Prism to replace its paper-based data collection system in a dose escalation study of the lead product from the company’s Cancer Survival Protein (CSP) drug discovery platform.
